Helping You Build Wealth With Honest Research
Since 1996. Read On...

MEMBER'S LOGIN

MEMBER'S LOGINX

     
Invalid Username / Password
   
     
   
     
 
Invalid Captcha
   
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

Revealed
India's Third Giant Leap

This Could be One of the Biggest Opportunities for Investors




Important: We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
By submitting your email address, you also sign up for Profit Hunter, a daily newsletter from Equitymaster
covering exciting investing ideas and opportunities in India.

AD

Indian stock markets open flat
Wed, 24 Dec 09:30 am

Barring China, majority of the Asian stock markets have opened the day on firm note with Japan (up 1.15%) and Taiwan (up 0.7%) leading the gainers. The Indian stock markets have opened flat today. Most of the sectoral indices have opened in the red with metal and realty stocks leading the pack of losers.

As we approach the end of 2014, what will be the risks the Indian markets could face in 2015? Read our edition of the 5 Minute Wrapup to know more.

The Sensex today is up by around 17 points (0.06%), while the NSE-Nifty is up by about 6 points (0.07%). The mid cap and small cap stocks have opened in the green with BSE Mid Cap index and BSE Small Cap index up by 0.08% and 0.11% respectively. The rupee is currently trading at Rs 63.40 to the US dollar.

Majority of the MNC pharma stocks have opened the day on a firm note, with Glaxosmithkline Pharma (GSK Pharma) and Novartis Ltd leading the pack of gainers. As per a financial daily, the Competition Commission of India (CCI) has given the green signal for GSK Pharma and Novartis deal. As per the deal, the UK-based parent company GlaxoSmithKline (GSK) will be acquiring the Swiss major's vaccine business, while the latter would purchase GSK's cancer drugs portfolio. The deal also involves purchase of the global human vaccines business of Novartis. Reportedly, as per the CCI, with regard to the vaccine deal, the said deal is not likely to have appreciable adverse effect on competition in India.

Majority of the automobile stocks have opened the day on a positive note with Ultratech Cement and Heildelberg Cement being the leading gainers. As per a financial daily, Ultratech Cement has entered into a deal with Jaiprakash Associates to buy two cement plants for US$ 852 m. This includes the debt component of the plants. Reportedly, both these plants are located in Madhya Pradesh. Jaiprakash has been selling assets in recent quarters to cut its heavy debt load and improve its balance sheet. For Ultratech, the deal will initially raise its cement capacity in India to 65 million tonnes per year from 60 million tones. This figure is expected to rise to 71 million tonnes a year by 2016.

For information on how to pick stocks that have the potential to deliver big returns, download our special report now!

View all commentaries | Archives

Read the latest Market Commentary


Equitymaster requests your view! Post a comment on "Indian stock markets open flat". Click here!

  
ABOUT EQUITYMASTER

Since 1996, Equitymaster has been the source for honest and credible opinions on investing in India. With solid research and in-depth analysis Equitymaster is dedicated towards making its readers- smarter, more confident and richer every day. Here's why hundreds of thousands of readers spread across more than 70 countries Trust Equitymaster.

PREMIUM PRODUCTS
QUICK LINKS
POPULAR TOPICS
TRENDING TOPICS
FREE NEWSLETTERS
EQUITYMASTER SUPPORTS
  • HelpYourNGO
  • You Tube
  • Linkedin
  • Twitter
  • Telegram
  • Google Play

Copyright © Equitymaster Research Private Limited (formerly Equitymaster Agora Research Private Limited).

Whitelist | Refer | Terms | Privacy | Contact | About | Sitemap

Phone +91-9136015013

Equitymaster Research Private Limited (formerly Equitymaster Agora Research Private Limited) (Research Analyst)
SEBI (Research Analysts) Regulations 2014, Registration No. INH000000537.

103, Regent Chambers, Above Status Restaurant, Nariman Point, Mumbai - 400 021. India.
Telephone: +91-22-61434055. Email: info@equitymaster.com. Website: www.equitymaster.com.
CIN:U74999MH2007PTC175407

Name of the Compliance & Grievance Officer: Ms Sonal Ramachandran
Telephone: +91-22-61434003 | Email: compliance@equitymaster.com

LEGAL DISCLAIMER:
Investment in securities market are subject to market risks. Read all the related documents carefully before investing.
Registration granted by SEBI and certification from NISM in no way guarantee performance of the intermediary or provide any assurance of returns to investors.

All rights reserved. Any act of copying, reproducing or distributing this newsletter whether wholly or in part, for any purpose without the permission of Equitymaster is strictly prohibited and shall be deemed to be copyright infringement.

Equitymaster Research Private Limited (formerly Equitymaster Agora Research Private Limited) (Research Analyst) bearing Registration No. INH000000537 (hereinafter referred as 'Equitymaster') is an independent equity research Company. Equitymaster is not an Investment Adviser. Information herein should be regarded as a resource only and should be used at one's own risk. This is not an offer to sell or solicitation to buy any securities and Equitymaster will not be liable for any losses incurred or investment(s) made or decisions taken/or not taken based on the information provided herein. Information contained herein does not constitute investment advice or a personal recommendation or take into account the particular investment objectives, financial situations, or needs of individual subscribers. Before acting on any recommendation, subscribers should consider whether it is suitable for their particular circumstances and, if necessary, seek an independent professional advice. This is not directed for access or use by anyone in a country, especially, USA, Canada or the European Union countries, where such use or access is unlawful or which may subject Equitymaster or its affiliates to any registration or licensing requirement. All content and information is provided on an 'As Is' basis by Equitymaster. Information herein is believed to be reliable but Equitymaster does not warrant its completeness or accuracy and expressly disclaims all warranties and conditions of any kind, whether express or implied. Equitymaster may hold shares in the company/ies discussed herein. As a condition to accessing Equitymaster content and website, you agree to our Terms and Conditions of Use, available here. The performance data quoted represents past performance and does not guarantee future results.